trending Market Intelligence /marketintelligence/en/news-insights/trending/jhotxpj2yw8m0ij8dv9fna2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Sirtex spurns Varian; recommends CDH Investments' A$33.60-per share bid

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Sirtex spurns Varian; recommends CDH Investments' A$33.60-per share bid

Months after agreeing to be acquired by Varian Medical Systems Inc., Australia's Sirtex Medical Ltd is now recommending an A$33.60-per-share takeover bid by CDH Investments to its shareholders.

CDH is joined by China Grand Pharmaceutical and Healthcare Holdings Ltd. on the offer to acquire all of Sirtex's shares. CDH and CGP's offer implies an A$1.9 billion market capitalization for Sirtex.

Sirtex said its board believes the offer is superior to Varian's A$28-per-share bid and is in the best interest of shareholders. Palo Alto, Calif.-based Varian had the option to match the offer by CDH but opted not to.

As a result, Sirtex is terminating its deal with Varian and will be paying about A$16 million to the latter as a result of backing away from the agreement.

CDH and CGP will be acquiring all of Sirtex's shares through a scheme of arrangement. Upon implementation, Sirtex shareholders will be entitled to A$33.60 in cash per share.

Eligible shareholders will also receive a dividend of up to 30 Australian cents per share prior to the completion of the scheme. The dividend will be deducted to the A$33.60-per-share cash consideration that the shareholders will receive.

The scheme is subject to certain conditions, including antitrust clearance.

Varian said separately June 14 that it would not lodge a counter proposal for Sirtex, which will pay a A$16 million reimbursement fee to the California company.